(MedPage Today) — The co-antibody therapy JNJ-4804 — a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) — showed clinically meaningful efficacy exceeding that of either drug alone in patients with highly refractory…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
